ISRCTN80658312已完成未知
Spironolactone TO Prevent cardiovascular events in early stage Chronic Kidney Disease (CKD): A pilot trial
niversity of Birmingham (UK)0 个研究点目标入组 500 人开始时间: 2013年4月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female, age over 18 years
- •2. Diagnosis of CKD stage 3
排除标准
- •1. Diabetes Mellitus
- •2. Terminal disease or felt otherwise unsuitable by their general practitioner
- •3. Chronic heart failure i.e. a clinical diagnosis or known ejection fraction <55%
- •4. Atrial fibrillation
- •5. Alcohol or drug abuse
- •6. Inability to comply with trial medication and follow-up
- •7. Documented previous hyperkalaemia or intolerance of spironolactone
- •8. Documented Addisonian crisis and/or on fludrocortisone
- •9. Severe hypertension: blood pressure >= 180/110 mmHg
- •10. Systolic blood pressure < 120mmHg
- •11. Recent acute kidney injury or hospital admission (within past 6 weeks)
- •12. Chronic diarrhoea
- •13. Albumin:creatinine ratio (ACR) >= 70mg/mmol
- •14. Serum potassium >= 5 mEq/L on screening blood test
- •15. Concomittant co-trimoxazole medication
- •16. Concomittant angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker medication
- •17. Pregnancy
研究者
相似试验
进行中（未招募）
不适用
Spironolactone to Prevent Cardiovascular Events in Early Stage Chronic Kidney Diseasechronic kidney diseaseEUCTR2012-000654-55-GBniversity of Birmingham240
已完成
4 期
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis PatientsEnd-stage Renal FailureNCT01687699Dialysis Outcomes Heart Failure Aldactone Study Group157
Unknown
3 期
Spironolactone on Acute Kidney Injury in Critically Ill PatientsAcute Kidney InjuryNCT03206658Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran90
招募中
1 期
Aspirin to prevent cardiovascular events in patients with pneumoniaPneumonia, Myocardial infarctionCTIS2023-504553-12-01Amsterdam UMC760
尚未招募
4 期
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)CardiotoxicityNeoplasmsChemotherapy EffectHeart FailureNCT06005259University of Sao Paulo264